United States

Back to map

Showing 211-220 of 328 grants

Title Institution Researcher Program Duration Total Award Amount
Identification of novel targets to increase human beta cell proliferation The Regents of the University of California, San Francisco Gregory Ku Cures 01-December-2020 to 30-June-2026 $975,000.00
Sparing ER stressed human beta cells with novel kinase inhibitors of the unfolded protein response (UPR) The Regents of the University of California, San Francisco Feroz Papa Cures 01-August-2023 to 31-July-2026 $960,000.00
Reducing Diabetes Distress in Adults with Type 1 Diabetes: A pragmatic trial in routine diabetes care. The Regents of the University of California, San Francisco Danielle Hessler Improving Lives 01-August-2023 to 31-July-2026 $1,743,010.00
Local delivery of immunomodulators to enable systemic immunosuppression-free efficient islet transplantation The Regents of the University of California, San Francisco Bhushan Kharbikar Cures 01-March-2024 to 28-February-2027 $285,000.00
Triple therapy for T1DM with insulin, semaglutide and dapagliflozin The Research Foundation of SUNY on behalf of University at Buffalo Paresh Dandona Improving Lives 01-January-2019 to 31-March-2026 $1,808,522.70
Project Equity The Sonia Nabeta Foundation Vivian Nabeta Mission 01-May-2024 to 30-April-2026 $245,172.00
Engineered Nanoparticles for Beta Cell-Targeted Therapeutics The University of Chicago Raghavendra Mirmira Cures 01-April-2023 to 31-March-2026 $897,822.00
Safety and efficacy assessment of Tegoprubart and calcineurin inhibitors- free immunosuppression therapy for pancreatic islet transplantation in patients with t1DM and chronic kidney disease. The University of Chicago Piotr Witkowski Cures 01-September-2025 to 31-August-2029 $8,500,000.00
A pilot study assessing the safety of using a monoclonal antibody against CD40 ligand to achieve a calcineurin inhibitor-free immunosuppression regimen in patients with type 1 diabetes mellitus (T1D) and problematic hypoglycemia undergoing islet cell transplantation The University of Chicago Piotr Witkowski Cures 01-February-2024 to 31-January-2026 $250,000.00
A pilot study assessing the safety of using a monoclonal antibody against CD40 ligand to achieve a calcineurin inhibitor-free immunosuppression regimen in patients with type 1 diabetes mellitus (T1D) and problematic hypoglycemia undergoing islet cell transplantation The University of Chicago Piotr Witkowski Cures 01-February-2025 to 31-January-2027 $1,000,000.00